Biotech Values

[ghmm]

ALKS:

Alkermes Announces Positive Topline Results From Phase 1 Study of ALKS 8700 for Treatment of Multiple Sclerosis

Novel, Oral Product Candidate Provided Monomethyl Fumarate Exposures Comparable to TECFIDERA®, With Favorable Gastrointestinal Tolerability

Company Plans to Initiate Pivotal Development Program for Twice-Daily Candidate in 2015

http://phx.corporate-ir.net/mobile.view?c=92211&v=203&d=1&id=2014678

The percentage of subjects with GI-related AEs was lower with ALKS 8700 (8.3%) compared to TECFIDERA (41.7%). In Part 3, the PK data of the extended-release formulations of ALKS 8700 provided new insights into approaches for once-daily dosing options, which Alkermes will continue to pursue.

If they stick to the plan it seems they will beat XNPT to market (at least in MS) for the twice-daily dose.